DEVELOPMENT OF LIQUISOLID FORMULATION FOR IMPROVED SUSTAINED RELEASE OF PROPRANOLOL HYDROCHLORIDE

Authors

  • ALIYAH ALIYAH Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia, 90245
  • EMILIA UTOMO Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia, 90245
  • ANDI DIAN PERMANA Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia, 90245
  • ERNAWATI Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia, 90245

DOI:

https://doi.org/10.22159/ijap.2021v13i2.40354

Keywords:

Liquisolid granules, Propranolol hydrochloride, Sustained release

Abstract

Objective: The aim of this study was to develop a liquisolid formulation of propranolol hydrochloride to obtain an improved sustained release profile by varying the ratio of liquid vehicles.

Methods: In this study, propranolol hydrochloride (PPH) was dispersed in the combination of propylene glycol and polysorbate 80, as the liquid vehicles, with different ratios. Eudragit® RL and Aerosil® were used as carrier and coating materials, respectively, to produce a dry and free-flowing powder. In addition, HPMC was used to amplify the retardation effect. The prepared formulations were evaluated for its physicochemical properties, including loss on drying, flow rate, angle of repose calculation, drug content analysis, FT-IR spectroscopy, as well as dissolution studies. The obtained dissolution profiles were subsequently fitted to the mathematical model in order to determine the drug kinetics.

Results: The results show that all formulations performed dry and free-flowing granules containing PPH in the range of 7-9%. Furthermore, all the prepared formulations were able to sustain the drug release for a total of 8 h in two different dissolution media, namely simulated gastric fluid and simulated intestinal fluid. F4 containing propylene glycol and polysorbate 80 (1:2) possessed the lowest drug release rate. It was also obtained that F1 and F3 followed first-order kinetics while F2, F4, and F5 complied with the Higuchi model.

Conclusion: Overall, there was no difference in all the dissolution profiles based on the calculation of the difference and similarities factor.

Downloads

Download data is not yet available.

References

Bose S, Kaur A, Sharma SK. A review on advances of sustained release drug delivery system. Int Res J Pharm 2013;4:1–5.

Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm 2008;362:102–8.

Gupta M, Brijesh R. A review on: sustained release technology. Int J Ther Appl 2012;8:18–23.

Badadhe S, Gawali V, Bhalsing M, Jadhav B. Sustained release dosage forms: an overview. Int J Innov Pharm Sci Res 2016;4:1194–211.

NP K, MT S, DH S, PK S. A review on liquisolid systems. J Drug Delivery Ther 2014;4:25–31.

Pawar JD, Jagtap RS, Doijad RC, Pol SV, Desai JR, Jadhav VV, et al. Liquisolid Compacts: a promising approach for solubility enhancement. J Drug Delivery Ther 2017;7:6–11.

Mokashi AA, Gaikwad SL. Formulation and evaluation of liquisolid compacts of lornoxicam. Int J Pharm Pharm Sci 2019;11:33–7.

Anil A, Thomas L, Sudheer P. Liquisolid compacts: an innovative approach for dissolution enhancement. Int J Pharm Pharm Sci 2018;10:11–7.

Jassimp ZE. Formulation and evaluation of furosemide liquisolid compact. Int J Appl Pharm 2017;9:39–48.

Nokhodchi A, Hentzschel CM, Leopold CS. Drug release from liquisolid systems: speed it up, slow it down. Expert Opin Drug Delivery 2011;8:191–205.

Sweetman SC. editor. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.

Yadav A, Jain DK. Formulation development and characterization of propranolol hydrochloride microballoons for gastroretentive floating drug delivery. Afr J Pharm Pharmacol 2011;5:1801–10.

Panda S, Varaprasad R, Priyanka K, Swain RP. Liquisolid technique: a novel approach for dosage form design. Int J Appl Pharm 2017;9:8–14.

Shah RB, Tawakkul MA, Khan MA. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech 2008;9:250–8.

Holowka EP, Bhatia SK. Controlled release systems. In: Drug Delivery: Materials Design and Clinical Perspective; 2014. p. 8–62.

Permana AD, Paredes AJ, Volpe Zanutto F, Anjani QK, Utomo E, Donnelly RF. Dissolving microneedle-mediated dermal delivery of itraconazole nanocrystals for improved treatment of cutaneous candidiasis. Eur J Pharm Biopharm 2020;154:50–61.

Permana AD, Tekko IA, McCrudden MTC, Anjani QK, Ramadon D, McCarthy HO, et al. Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. J Controlled Release 2019;316:34–52.

Permana AD, McCrudden MTC, Donnelly RF. Enhanced intradermal delivery of nanosuspensions of antifilariasis drugs using dissolving microneedles: a proof of concept study. Pharmaceutics 2019;11:1–22.

Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–33.

Lu M, Xing H, Jiang J, Chen X, Yang T, Wang D, et al. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci 2017;12:115–23.

Sahoo J, Murthy PN, Biswal S, Sahoo SK, Mahapatra AK. Comparative study of propranolol hydrochloride release from matrix tablets with Kollidon®SR or hydroxy propyl methyl cellulose. AAPS PharmSciTech 2008;9:577–82.

Rowe RC, Sheskey PJ, Quinn ME. editors. Handbook of Pharmaceutical Excipients. Sixth. London: Pharmaceutical Press; 2009.

Balaji A, Umashankar MS, Kavitha B. Liquisolid technology-a latest review. Int J Appl Pharm 2014;6:11–9.

The United States Pharmacopeial Convention. USP 35. Vol. 35. U. S. Pharmacopoeia; 2012. p. 801–4.

Chaturvedi K, Umadevi S, Vaghani S. Floating matrix dosage form for propranolol hydrochloride based on gas formation technique: development and in vitro evaluation. Sci Pharm 2010;78:927–39.

Hernawan, Nurhayati S, Nisa K, Indrianingsih AW, Darsih C, Kismurtono M. Formulation and in vitro study of propranolol hydrochloride controlled release from carboxymethyl chitosan-based matrix tablets. Indones J Chem 2013;13:242–7.

Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci 2006;19:119–24.

Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Delivery Rev 2012;64:163–74.

Adibkia K, Shokri J, Barzegar Jalali M, Solduzian M, Javadzadeh Y. Effect of solvent type on retardation properties of diltiazem HCl form liquisolid tablets. Colloids Surfaces B Biointerfaces 2014;113:10–4.

Wojcik Pastuszka D, Krzak J, Macikowski B, Berkowski R, Osiński B, Musiał W. Evaluation of the release kinetics of a pharmacologically active substance from model intra-articular implants replacing the cruciate ligaments of the knee. Materials (Basel) 2019;12:1208.

Paarakh MP, Jose PANI, Setty CM, Peter GV. Release kinetics–concepts and applications. Int J Pharm Res Technol 2019;8:12–20.

Gouda R, Baishya H, Qing Z. Application of mathematical models in drug release kinetics of carbidopa and levodopa ER tablets. J Dev Drugs 2017;6:1–8.

Published

07-03-2021

How to Cite

ALIYAH, A., UTOMO, E., PERMANA, A. D., & ERNAWATI. (2021). DEVELOPMENT OF LIQUISOLID FORMULATION FOR IMPROVED SUSTAINED RELEASE OF PROPRANOLOL HYDROCHLORIDE. International Journal of Applied Pharmaceutics, 13(2), 210–216. https://doi.org/10.22159/ijap.2021v13i2.40354

Issue

Section

Original Article(s)